GlassScriptPhysician profile
Michael M Amiri
NPI 1720161011
$30,942.00
in general payments reported to CMS, 2019-2025
89 companies · $5,635 in 2025
The $5,635 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,271 · 2020: $3,008 · 2021: $4,144 · 2022: $5,093 · 2023: $4,588 · 2024: $4,204 · 2025: $5,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Travel and Lodging: $616 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,494.61 |
| Travel and Lodging | $615.75 |
| Education | $316.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,422.39 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,116.60 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $1,628.73 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Eisai INC. | $1,593.70 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $1,373.37 | 2019-2022 | |
| Abbvie INC. | $1,365.09 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Neurelis, INC. | $1,299.93 | 2020-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $1,012.52 | 2019-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $987.46 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Pfizer INC. | $968.08 | 2019-2025 | |
| Biogen, INC. | $846.39 | 2021-2025 | Vumerity, Plegridy, Avonex |
| Sk Life Science, INC. | $814.90 | 2020-2025 | Xcopri |
| Jazz Pharmaceuticals INC. | $704.63 | 2019-2025 | Epidiolex |
| Mdd US Operations, LLC | $699.96 | 2019-2025 | Xadago, Apokyn, Apokyn |
| Inspire Medical Systems, INC. | $679.76 | 2023-2025 | Inspire |
Show all 89 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Amiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.